🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04982588
Active, not recruiting Not applicable

Evolut PRO China Clinical Study

NCT04982588 · tracked via the Priya Life Science China tracker
Sponsor
Medtronic Cardiovascular
Phase
Not applicable
Started
2021-07-17
Last updated
2025-12-03

Condition(s) studied

Severe, Symptomatic Aortic Stenosis

Investigational drug(s) / intervention(s)

Medtronic CoreValve™ Evolut™ PRO System

Medtronic CoreValve™ Evolut™ PRO System: The system comprised of the following three components: 1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV) 2. EnVeo™ PRO Delivery Catheter System (DCS) 3. EnVeo™ PRO Loading System (LS)

Study summary

Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).

Eligibility

Sex
ALL
Min age
65 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Aortic valve area (AVA) \< 1.0 cm2 (or indexed AVA \<0.6 cm2/m2) OR mean gradient \> 40 mmHg, OR max aortic velocity \> 4.0 m/sec 2. High risk for SAVR defined as STS-PROM score ≥ 8% AND ≤ 15%, OR documented Heart Team agreement of high risk for AVR due to frailty or comorbidities 3. Symptoms of aortic stenosis and NYHA ≥ II Exclusion Criteria: 1. Age is less than 65 years old 2. Non-calcified aortic valve 3. Bicuspid aortic valve with no raphe or 2 raphes (Sievers classification type 0 or type 2) 4. Ascending aortic diameter \> 4.5 cm

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Beijing Anzhen Hospital, Capital Medical University Beijing Beijing Municipality
Chinese PLA General Hospital, Chinese PLA Medical School Beijing Beijing Municipality
West China Hospital of Sichuan University Chengdu Sichuan
The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang

More Medtronic Cardiovascular trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04982588 on ClinicalTrials.gov ↗ ← All trials in China